163 related articles for article (PubMed ID: 32237268)
21. Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.
Cines DB; Yarovoi SV; Zaitsev SV; Lebedeva T; Rauova L; Poncz M; Arepally GM; Khandelwal S; Stepanova V; Rux AH; Cuker A; Guo C; Ocariza LM; Travers RJ; Smith SA; Kim H; Morrissey JH; Conway EM
Blood Adv; 2016 Nov; 1(1):62-74. PubMed ID: 29296696
[TBL] [Abstract][Full Text] [Related]
22. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
23. Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT.
Krauel K; Preuße P; Warkentin TE; Trabhardt C; Brandt S; Jensch I; Mandelkow M; Hammer E; Hammerschmidt S; Greinacher A
Blood; 2019 Feb; 133(9):978-989. PubMed ID: 30573633
[TBL] [Abstract][Full Text] [Related]
24. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.
Lee CSM; Selvadurai MV; Pasalic L; Yeung J; Konda M; Kershaw GW; Favaloro EJ; Chen VM
J Thromb Haemost; 2022 Apr; 20(4):975-988. PubMed ID: 35038779
[TBL] [Abstract][Full Text] [Related]
25. Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia.
Nazi I; Arnold DM; Warkentin TE; Smith JW; Staibano P; Kelton JG
J Thromb Haemost; 2015 Oct; 13(10):1900-7. PubMed ID: 26291604
[TBL] [Abstract][Full Text] [Related]
26. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A
J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520
[TBL] [Abstract][Full Text] [Related]
27. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.
Padmanabhan A; Jones CG; Bougie DW; Curtis BR; McFarland JG; Wang D; Aster RH
Blood; 2015 Jan; 125(1):155-61. PubMed ID: 25342714
[TBL] [Abstract][Full Text] [Related]
28. The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia.
Huynh A; Arnold DM; Smith JW; Elliott TD; Ivetic N; Kelton JG; Nazy I
Thromb Res; 2020 Oct; 194():135-141. PubMed ID: 32788105
[TBL] [Abstract][Full Text] [Related]
29. Distinct Binding Characteristics of Pathogenic Anti-Platelet Factor-4/Polyanion Antibodies to Antigens Coated on Different Substrates: A Perspective on Clinical Application.
Nguyen TH; Greinacher A
ACS Nano; 2018 Dec; 12(12):12030-12041. PubMed ID: 30540167
[TBL] [Abstract][Full Text] [Related]
30. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia.
Denomme GA; Warkentin TE; Horsewood P; Sheppard JA; Warner MN; Kelton JG
J Lab Clin Med; 1997 Sep; 130(3):278-84. PubMed ID: 9341987
[TBL] [Abstract][Full Text] [Related]
31. Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.
Prechel MM; Jeske WP; Walenga JM
Thromb Res; 2010 Apr; 125(4):e143-8. PubMed ID: 19931120
[TBL] [Abstract][Full Text] [Related]
32. Dynamic antibody-binding properties in the pathogenesis of HIT.
Sachais BS; Litvinov RI; Yarovoi SV; Rauova L; Hinds JL; Rux AH; Arepally GM; Poncz M; Cuker A; Weisel JW; Cines DB
Blood; 2012 Aug; 120(5):1137-42. PubMed ID: 22577175
[TBL] [Abstract][Full Text] [Related]
33. Development of a high-yield expression and purification system for platelet factor 4.
Huynh A; Arnold DM; Moore JC; Smith JW; Kelton JG; Nazy I
Platelets; 2018 May; 29(3):249-256. PubMed ID: 29172900
[TBL] [Abstract][Full Text] [Related]
34. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin.
Amiral J; Peynaud-Debayle E; Wolf M; Bridey F; Vissac AM; Meyer D
Am J Hematol; 1996 Jun; 52(2):90-5. PubMed ID: 8638647
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia.
Horne MK; Hutchison KJ
Am J Hematol; 1998 May; 58(1):24-30. PubMed ID: 9590145
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.
Kelton JG; Smith JW; Warkentin TE; Hayward CP; Denomme GA; Horsewood P
Blood; 1994 Jun; 83(11):3232-9. PubMed ID: 8193358
[TBL] [Abstract][Full Text] [Related]
37. Role of monocytes and endothelial cells in heparin-induced thrombocytopenia.
Madeeva D; Cines DB; Poncz M; Rauova L
Thromb Haemost; 2016 Oct; 116(5):806-812. PubMed ID: 27487857
[TBL] [Abstract][Full Text] [Related]
38. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
Krauel K; Hackbarth C; Fürll B; Greinacher A
Blood; 2012 Feb; 119(5):1248-55. PubMed ID: 22049520
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies.
Brodard J; Kremer Hovinga JA; Fontana P; Studt JD; Gruel Y; Greinacher A
J Thromb Haemost; 2021 May; 19(5):1294-1298. PubMed ID: 33550713
[TBL] [Abstract][Full Text] [Related]
40. Bacteria exploit platelets.
Naik UP
Blood; 2014 May; 123(20):3067-8. PubMed ID: 24832941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
